MediciNova, Inc. (TYO:4875)
Japan · Delayed Price · Currency is JPY | Market Cap | 12.00B +26.4% |
| Revenue (ttm) | 149.62M +583.9% |
| Net Income | -1.75B |
| EPS | -35.56 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,600 |
| Open | 241.00 |
| Previous Close | 241.00 |
| Day's Range | 230.00 - 253.00 |
| 52-Week Range | 174.00 - 510.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute res... [Read more]
News
MediciNova to Participate in the Maxim Growth Summit
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001
MediciNova (MNOV) announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease associat...
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat MN-001 showed ...
MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166
MediciNova (MNOV) announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 for the treatment of Amyotrophic Lat...
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova initiated with a Buy at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan initiated coverage of MediciNova (MNOV) with a Buy rating and $6 price target The firm cites the unmet need in amyotrophic lateral sclerosis treatment as…
MediciNova Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two pivotal clinical readouts—MN-001 in September and COMBAT-ALS by year-end—are set to drive near-term value, supported by a strong cash position and a lean, capital-efficient model. Externally funded programs and regulatory designations add further optionality.
MediciNova to Participate in Two Investor Conferences in September
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova Quarterly report: Q2 2026
MediciNova has published its Q2 2026 quarterly earnings report on August 13, 2026.
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova CEO Provides Shareholder Update
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (...
MediciNova Slides: Corporate presentation
MediciNova has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
MediciNova Quarterly report: Q1 2026
MediciNova has published its Q1 2026 quarterly earnings report on May 14, 2026.
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
MediciNova’s peer-reviewed ibudilast study advances clinical translation
The company states: “MediciNova (MNOV) and the Standard Market of the Tokyo Stock Exchange announced that a study conducted by researchers at the Spanish National Cancer Research Centre has identified...
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
MediciNova Proxy statement: Proxy filing
MediciNova filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Maxim resumes MediciNova at Buy on potential value-driving data events this year
Maxim analyst Michael Okunewitch resumed coverage of MediciNova (MNOV) with a Buy rating and $6 price target The firm is positive on the company’s potential value-driving data events in 2026,…
MediciNova resumed with a Buy at Maxim
Maxim resumed coverage of MediciNova (MNOV) with a Buy rating and $6 price target
MediciNova to Participate at the 38th Annual ROTH Conference
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
MediciNova initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of MediciNova (MNOV) with a Buy rating and $10 price target MediciNova is a clinical-stage biotechnology company developing multi-target small molecule therapies acr...